Literature DB >> 26292790

Rituximab as a first-line treatment in pediatric neuromyelitis optica spectrum disorder.

Giorgia Olivieri1, Viviana Nociti2,3, Raffaele Iorio4, Maria Chiara Stefanini1, Francesco Antonio Losavio4, Massimiliano Mirabella4, Paolo Mariotti1.   

Abstract

Entities:  

Keywords:  Aquaporin-4; First-line therapy; Pediatric NMOSD; Rituximab

Mesh：

Substances：

Year:  2015        PMID： 26292790     DOI： 10.1007/s10072-015-2368-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  4 in total

1.  Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.

Authors:  Russell C Dale; Fabienne Brilot; Lisa V Duffy; Marinka Twilt; Amy T Waldman; Sona Narula; Eyal Muscal; Kumaran Deiva; Erik Andersen; Michael R Eyre; Despina Eleftheriou; Paul A Brogan; Rachel Kneen; Gulay Alper; Banu Anlar; Evangeline Wassmer; Kirsten Heineman; Cheryl Hemingway; Catherine J Riney; Andrew Kornberg; Marc Tardieu; Amber Stocco; Brenda Banwell; Mark P Gorman; Susanne M Benseler; Ming Lim
Journal:  Neurology       Date:  2014-06-11       Impact factor: 9.910

2.  Distinctive clinical and neuroimaging characteristics of longitudinally extensive transverse myelitis associated with aquaporin-4 autoantibodies.

Authors:  Raffaele Iorio; Valentina Damato; Massimiliano Mirabella; Amelia Evoli; Alessandro Marti; Domenico Plantone; Giovanni Frisullo; Anna Paola Batocchi
Journal:  J Neurol       Date:  2013-06-21       Impact factor: 4.849

3.  A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.

Authors:  Vanda A Lennon; Dean M Wingerchuk; Thomas J Kryzer; Sean J Pittock; Claudia F Lucchinetti; Kazuo Fujihara; Ichiro Nakashima; Brian G Weinshenker
Journal:  Lancet       Date:  2004 Dec 11-17       Impact factor: 79.321

4.  Rituximab as a first-line preventive treatment in pediatric NMOSDs: Preliminary results in 5 children.

Authors:  Giulia Longoni; Brenda Banwell; Massimo Filippi; E Ann Yeh
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2014-12-11
  4 in total
  2 in total

1.  Use of Rituximab and Risk of Re-hospitalization for Children with Neuromyelitis Optica Spectrum Disorder.

Authors:  Sabrina Gmuca; Rui Xiao; Pamela F Weiss; Amy T Waldman; Jeffrey S Gerber
Journal:  Mult Scler Demyelinating Disord       Date:  2018-04-17

2.  Effectiveness of rituximab in neuromyelitis optica: a meta-analysis.

Authors:  Fulin Gao; Bingyan Chai; Cheng Gu; Ruipeng Wu; Tong Dong; Yuping Yao; Yi Zhang
Journal:  BMC Neurol       Date:  2019-03-06       Impact factor: 2.474
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.